Literature DB >> 17299423

Dental treatment and risk of variant CJD--a case control study.

D Everington1, A J Smith, H J T Ward, S Letters, R G Will, J Bagg.   

Abstract

OBJECTIVE: Knowledge of risk factors for variant CJD (vCJD) remains limited, but transmission of prion proteins via re-useable medical devices, including dental instruments, or enhanced susceptibility following trauma to the oral cavity is a concern. This study aimed to identify whether previous dental treatment is a risk factor for development of vCJD.
DESIGN: Case control study.
METHODS: Risk factor questionnaires completed by interview with relatives of 130 vCJD patients and with relatives of 66 community and 53 hospital controls were examined by a dental surgeon. Responses regarding dental treatments were analysed.
RESULTS: We did not find a statistically significant excess of risk of vCJD associated with dental treatments with the exception of extractions in an unmatched analysis of vCJD cases with community controls (p = 0.02). However, this result may be explained by multiple testing.
CONCLUSIONS: This is the first published study to date to examine potential links between vCJD and dental treatment. There was no convincing evidence found of an increased risk of variant CJD associated with reported dental treatment. However, the power of the study is restricted by the number of vCJD cases to date and does not preclude the possibility that some cases have resulted from secondary transmission via dental procedures. Due to the limitations of the data available, more detailed analyses of dental records are required to fully exclude the possibility of transmission via dental treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17299423     DOI: 10.1038/bdj.2007.126

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  7 in total

1.  Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review.

Authors:  Matt Stevenson; Lesley Uttley; Jeremy E Oakley; Christopher Carroll; Stephen E Chick; Ruth Wong
Journal:  Health Technol Assess       Date:  2020-02       Impact factor: 4.014

2.  Bacterial colitis increases susceptibility to oral prion disease.

Authors:  Christina J Sigurdson; Mathias Heikenwalder; Giuseppe Manco; Manja Barthel; Petra Schwarz; Bärbel Stecher; Nike J Krautler; Wolf-Dietrich Hardt; Burkhardt Seifert; Andrew J S MacPherson; Irène Corthesy; Adriano Aguzzi
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 3.  How do PrPSc Prions Spread between Host Species, and within Hosts?

Authors:  Neil A Mabbott
Journal:  Pathogens       Date:  2017-11-24

4.  A clinicopathological study of selected cognitive impairment cases in Lothian, Scotland: enhanced CJD surveillance in the 65 + population group.

Authors:  Lovney Kanguru; Gemma Logan; Briony Waddel; Colin Smith; Anna Molesworth; Richard Knight
Journal:  BMC Geriatr       Date:  2022-07-20       Impact factor: 4.070

5.  Late-in-life surgery associated with Creutzfeldt-Jakob disease: a methodological outline for evidence-based guidance.

Authors:  Mabel Cruz; Ignacio Mahillo-Fernandez; Alberto Rábano; Ake Siden; Miguel Calero; Henning Laursen; Kåre Mølbak; Javier Almazán; Jesus de Pedro-Cuesta
Journal:  Emerg Themes Epidemiol       Date:  2013-05-23

6.  Bioassay studies support the potential for iatrogenic transmission of variant Creutzfeldt Jakob Disease through dental procedures.

Authors:  Elizabeth Kirby; Joanne Dickinson; Matthew Vassey; Mike Dennis; Mark Cornwall; Neil McLeod; Andrew Smith; Philip D Marsh; James T Walker; J Mark Sutton; Neil D H Raven
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001-2004.

Authors:  Jessica Ruegger; Katharina Stoeck; Lorenz Amsler; Thomas Blaettler; Marcel Zwahlen; Adriano Aguzzi; Markus Glatzel; Klaus Hess; Tobias Eckert
Journal:  BMC Public Health       Date:  2009-01-14       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.